SEC Comment Letter 0000000000-24-013902 to Prime Medicine, Inc. (PRME) (CIK 0001894562) (PRME)
Prime Medicine, Inc. (PRME) (CIK 0001894562)
Date: Dec. 17, 2024 · CIK: 0001894562 · Accession: 0000000000-24-013902
AI Filing Summary & Sentiment
File numbers found in text: 333-283780
Letter
December 17, 2024 Keith Gottesdiener Chief Executive Officer Prime Medicine, Inc. 60 First Street Cambridge, MA 02141 Re:Prime Medicine, Inc. Registration Statement on Form S-3 Filed December 13, 2024 File No. 333-283780 Dear Keith Gottesdiener: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
December 17, 2024
Keith Gottesdiener
Chief Executive Officer
Prime Medicine, Inc.
60 First Street
Cambridge, MA 02141
Re:Prime Medicine, Inc.
Registration Statement on Form S-3
Filed December 13, 2024
File No. 333-283780
Dear Keith Gottesdiener:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences